Attivare Therapeutics
Natick · Founded 2020
About Attivare Therapeutics
Attivare Therapeutics is a biotechnology company focused on discovering and developing small-molecule therapies that modulate immune and inflammatory pathways. The company’s research centers on activating specific biological mechanisms involved in innate immunity to address diseases where immune response plays a central role. Its pipeline includes orally administered drug candidates designed to target well-defined molecular pathways, with an emphasis on translating foundational immunology research into clinical applications. Attivare Therapeutics conducts preclinical and clinical development activities, including target validation, medicinal chemistry, pharmacology, and safety evaluation. The company also engages in translational research to identify biomarkers that support patient selection and therapeutic monitoring. Through collaborations with academic researchers and industry partners, Attivare Therapeutics advances programs aimed at treating inflammatory, autoimmune, and immune-mediated conditions.
Company Facts
- Founded: 2020
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $12.6M
- Funding stage: Seed
- Last round: Grant (Dec 2025)
- Website: https://attivaretx.com
Industries & Categories
Biotechnology, Health Care, Life Science, Therapeutics
Canonical: https://fsome.com/organization/attivare-therapeutics-22903 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.